News
NRXP
3.040
+0.66%
0.020
Nrx Pharmaceuticals Inc: Current report
Press release · 5h ago
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
NASDAQ · 11h ago
Nasdaq Down 0.5%; Lithium Americas Shares Slide
U.S. Stocks traded mostly lower toward the end of trading on Thursday. The Dow traded down 0.01% while the NASDAQ Composite fell around 0.5%. D.R. Horton, Inc. Reported better-than-expected second-quarter financial results. Asian markets closed mostly higher in Asia Pacific markets.
Benzinga · 1d ago
CGC, GENE and HOLO among mid-day movers
Seeking Alpha · 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 1d ago
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
Benzinga · 1d ago
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Las Vegas Sands Corp. Shares dipped 6.8% to $46.81 on Thursday. The company reported better-than-expected first-quarter results. AGBA Group Holding Limited shares jumped 148% after the company announced a merger agreement with Triller. Other stocks moving in the mid-day session included 23andMe Holding Co. And Vertex Pharmaceuticals.
Benzinga · 1d ago
Why Is Bio-Path (BPTH) Stock Up 89% Today?
BPTH stock is up 89.1% as of Thursday morning. More than 40 million shares of Bio-Path stock are changing hands. The clinical trial progress of BPTH stock brings with it heavy trading of the stock. AGBA Group, Tesla (TSLA) and NRX Pharmaceuticals (NRXP) stock are also in the news.
Investorplace · 1d ago
Why Is AGBA Group (AGBA) Stock Up 149% Today?
Investorplace · 1d ago
Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings
Benzinga · 1d ago
NRx Pharmaceuticals Shares Drop 27% After Public Offering Prices
Dow Jones · 1d ago
Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?
Investorplace · 1d ago
NRx Pharmaceuticals receives Nasdaq notice on demonstrating compliance with bid price requirement
Seeking Alpha · 1d ago
NRx Pharmaceuticals, Inc. Announces Pricing Of $2M Underwritten Public Offering Of Common Stock At A Public Offering Price Of $3.30 Per Share
Benzinga · 1d ago
INVO, EZGO and WISA among pre-market losers
Seeking Alpha · 1d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 1d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investorplace · 1d ago
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Alcoa Corporation rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter. The company shares jumped 3% to $36.60 in pre- market trading. Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) shares gained 155.6% in today's trading.
Benzinga · 1d ago
NRx Pharma Shares Fall on Public Offering Plan
Shares of NRx Pharmaceuticals dropped 18% in after-market trading. The company said it would sell shares in an underwritten public offering. The stock was down 18% at $3.43 in after market trading. Shares had fallen 9% year to date. Proceeds from the offering will be used for working capital.
Dow Jones · 2d ago
More
Webull provides a variety of real-time NRXP stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXP
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.